News articles about Athenex (NASDAQ:ATNX) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Athenex earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.4119935722285 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Athenex to Present at 29th Annual Piper Jaffray Healthcare Conference (finance.yahoo.com)
- ESMO Asia 2017: Oraxol (oral paclitaxel, Athenex) Can Achieve Similar Exposure to IV Paclitaxel in Cancer Patients (finance.yahoo.com)
- Athenex, Inc. – Value Analysis (NASDAQ:ATNX) : November 20, 2017 (finance.yahoo.com)
- Zacks: Analysts Set $25.73 Price Target for Athenex, Inc. (ATNX) (americanbankingnews.com)
- Athenex, Inc. breached its 50 day moving average in a Bullish Manner : ATNX-US : November 17, 2017 (finance.yahoo.com)
Shares of Athenex (ATNX) opened at $18.14 on Thursday. Athenex has a twelve month low of $11.21 and a twelve month high of $20.79.
Several analysts have recently issued reports on ATNX shares. Laidlaw started coverage on shares of Athenex in a research report on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price target on the stock. J P Morgan Chase & Co started coverage on shares of Athenex in a research report on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price target on the stock. Credit Suisse Group started coverage on shares of Athenex in a research report on Monday, September 18th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, Royal Bank Of Canada started coverage on shares of Athenex in a research report on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Athenex currently has a consensus rating of “Buy” and an average price target of $27.64.
WARNING: This piece of content was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/23/athenex-atnx-given-coverage-optimism-rating-of-0-08.html.
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.